Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trialfor Metastatic Clear Cell Renal Cell Carcinoma387 locations incl. BirminghamSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT04510597·Phase 3·RecruitingApply to this trial
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Studyfor Clinical Stage III Cutaneous Melanoma AJCC v8Drug: Cabozantinib223 locations incl. PhoenixSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT05136196·Phase 2·RecruitingApply to this trial
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancerfor Oropharyngeal p16INK4a-Negative Squamous Cell CarcinomaDrug: Atezolizumab338 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT01810913·Phase 2, Phase 3·RecruitingApply to this trial
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)for Acute Myeloid LeukemiaDrug: Venetoclax225 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT06317649·Phase 2·RecruitingApply to this trial
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trialfor Castration-Sensitive Prostate CarcinomaDrug: Apalutamide195 locations incl. TucsonSponsor: Alliance for Clinical Trials in OncologySex: Male·Age: 18+Code: NCT06931340·Phase 3·RecruitingApply to this trial
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancerfor Locally Advanced Urothelial Carcinoma152 locations incl. PhoenixSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT06524544·Phase 3·RecruitingApply to this trial
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trialfor Recurrent Endometrial CarcinomaDrug: Selumetinib293 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: Female·Age: 18+Code: NCT05554328·Phase 2·RecruitingApply to this trial
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancerfor Castration Levels of Testosterone334 locations incl. GilbertSponsor: SWOG Cancer Research NetworkSex: Male·Age: 18+Code: NCT03678025·Phase 3·RecruitingApply to this trial
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Studyfor Muscle Invasive Bladder Urothelial Carcinoma211 locations incl. Fort SmithSponsor: NRG OncologySex: All·Age: 18+Code: NCT07097142·Phase 3·RecruitingApply to this trial
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Studyfor Metastatic Colorectal Adenocarcinoma185 locations incl. KingmanSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18+Code: NCT05673148·Phase 3·RecruitingApply to this trial
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)for Malignant Female Reproductive System Neoplasm187 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT06126276·Phase 2·RecruitingApply to this trial
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)for Acute Myeloid Leukemia129 locations incl. TucsonSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT06672146·Phase 2·RecruitingApply to this trial
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemiafor B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative276 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT03739814·Phase 2·RecruitingApply to this trial
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancerfor Prostate Adenocarcinoma402 locations incl. BirminghamSponsor: NRG OncologySex: Male·Age: 18+Code: NCT05946213·Phase 3·RecruitingApply to this trial
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancerfor Hematopoietic and Lymphatic System Neoplasm190 locations incl. BirminghamSponsor: Children's Oncology GroupSex: Female·Age: Up to 39Code: NCT06513962·Phase 3·RecruitingApply to this trial
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistulafor Pancreatic Carcinoma118 locations incl. BirminghamSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT06807437·Phase 3·RecruitingApply to this trial
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trialfor Advanced Hepatocellular Carcinoma138 locations incl. BerkeleySponsor: NRG OncologySex: All·Age: 18+Code: NCT07166406·Phase 3·RecruitingApply to this trial
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphomafor Diffuse Large B-Cell Lymphoma87 locations incl. TucsonSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT05633615·Phase 2·RecruitingApply to this trial
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomasfor Metastatic Dedifferentiated Liposarcoma246 locations incl. PhoenixSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT06422806·Phase 3·RecruitingApply to this trial
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancerfor Astrocytoma, IDH-Mutant, Grade 3Drug: Vorasidenib82 locations incl. DuarteSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 12+Code: NCT07215910·Phase 3·RecruitingApply to this trial
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgeryfor Grade 2 Meningioma198 locations incl. BirminghamSponsor: NRG OncologySex: All·Age: 18+Code: NCT03180268·Phase 3·RecruitingApply to this trial
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Bodyfor Castration-Resistant Prostate Carcinoma174 locations incl. FayettevilleSponsor: SWOG Cancer Research NetworkSex: Male·Age: 18+Code: NCT06470243·Phase 3·RecruitingApply to this trial
Project: Every Child for Younger Patients With Cancerfor Adrenal Gland Pheochromocytoma245 locations incl. BirminghamSponsor: Children's Oncology GroupSex: All·Age: Up to 25Code: NCT02402244·RecruitingApply to this trial
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinomafor Endometrial AdenocarcinomaDrug: Ipilimumab137 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: Female·Age: 18+Code: NCT05112601·Phase 2·RecruitingApply to this trial
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinomafor Recurrent Head and Neck Squamous Cell Carcinoma178 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: All·Age: 18 - 79Code: NCT04671667·Phase 2·RecruitingApply to this trial
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatmentfor Grade 3b Follicular Lymphoma104 locations incl. TucsonSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT05890352·Phase 2·RecruitingApply to this trial
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcomafor High Grade OsteosarcomaDrug: Cabozantinib177 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: All·Age: Up to 40Code: NCT05691478·Phase 2, Phase 3·RecruitingApply to this trial
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyfor B Acute Lymphoblastic Leukemia203 locations incl. BirminghamSponsor: Children's Oncology GroupSex: All·Age: 365 Days - 25Code: NCT03959085·Phase 3·RecruitingApply to this trial
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)for B Acute Lymphoblastic Leukemia141 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: All·Age: 366 Days - 46Code: NCT06124157·Phase 2·RecruitingApply to this trial
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutationsfor Acute Myeloid Leukemia185 locations incl. BirminghamSponsor: Children's Oncology GroupSex: All·Age: Up to 21Code: NCT04293562·Phase 3·RecruitingApply to this trial
Stroke Thrombectomy and Aneurysm Registryfor Stroke54 locations incl. BirminghamSponsor: Medical University of South CarolinaSex: All·Age: 1 - 120Code: NCT04994756·RecruitingApply to this trial
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)for Recurrent T Acute Lymphoblastic Leukemia163 locations incl. BirminghamSponsor: SWOG Cancer Research NetworkSex: All·Age: 12+Code: NCT04315324·Phase 1, Phase 2·RecruitingApply to this trial
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Studyfor Acute Lymphoblastic Leukemia164 locations incl. BirminghamSponsor: PedAL BCU, LLCSex: All·Age: Up to 22Code: NCT04726241·Phase 1, Phase 2·RecruitingApply to this trial
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWTfor Anaplastic Kidney Wilms Tumor177 locations incl. BirminghamSponsor: Children's Oncology GroupSex: All·Age: Up to 30Code: NCT04322318·Phase 2·RecruitingApply to this trial
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcomafor Metastatic Malignant Neoplasm in the Lung219 locations incl. BirminghamSponsor: Children's Oncology GroupSex: All·Age: Up to 50Code: NCT05235165·Phase 3·RecruitingApply to this trial
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCTfor Central Nervous System Nongerminomatous Germ Cell Tumor149 locations incl. BirminghamSponsor: Children's Oncology GroupSex: All·Age: 3 - 29Code: NCT04684368·Phase 2·RecruitingApply to this trial
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)for Stage I Mixed Cell Type Kidney Wilms Tumor146 locations incl. BirminghamSponsor: Children's Oncology GroupSex: All·Age: Up to 30Code: NCT06401330·Phase 3·RecruitingApply to this trial
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)for Down SyndromeDrug: Nivolumab209 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: All·Age: 1 - 30Code: NCT04546399·Phase 2·RecruitingApply to this trial
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcomafor Embryonal Rhabdomyosarcoma165 locations incl. BirminghamSponsor: Children's Oncology GroupSex: All·Age: Up to 21Code: NCT05304585·Phase 3·RecruitingApply to this trial
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosisfor AL Amyloidosis117 locations incl. GoodyearSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT06022939·Phase 3·RecruitingApply to this trial